Results 31 to 40 of about 76,806 (261)
The term non-Hodgkin lymphoma (NHL) covers a spectrum of malignant disorders arising from cells of the immune system and manifesting predominantly as lymphadenopathy or solid tumour. The classification of NHL is complex and ever-evolving, with more than 50 different subtypes listed in the latest WHO classification of lymphoma (1).
Bowzyk Al-Naeeb, Anna +3 more
openaire +3 more sources
This study establishes [68Ga]Ga‐DOTA‐AP9 as a first‐in‐human CD147‐targeted PET tracer with favorable safety and specific tumor uptake. Tracer accumulation correlates with CD147 expression in patients, enabling noninvasive quantification of CD147‐positive malignancies.
Xiaokun Ma +10 more
wiley +1 more source
Cerebral type MALT non Hodgkin lymphoma
Introduction: Non-Hodgkin's lymphomas generally have their origin in the lymphoid system, there is a great diversity of them, which makes their classification and definitive pathological diagnosis difficult.
Yaimara Zunen Hernández Puentes +3 more
doaj
CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma
Chemotherapy and hematopoietic stem cell transplantation are effective treatments for most Hodgkin lymphoma patients, however there remains a need for better tumor-specific target therapy in Hodgkin lymphoma patients with refractory or relapsed disease ...
Ziduo Li +21 more
doaj +1 more source
HIV ASSOCIATED LYMPHOMA – TWO CASE REPORT SERIES [PDF]
Combined antiretroviral therapy significantly improved the prognosis and the life expectancy of HIV patients. Along with this, the profile of HIV associated malignant pathologies has changed. Among these, lymphoma, with a higher incidence than in general
Liana-Cătălina Gavriliu +1 more
doaj +1 more source
Glucose deprivation in the primary CNS lymphoma (PCNSL) tumor microenvironment drives SLC2A5 (encoding GLUT5)‐dependent fructose metabolism in tumor cells, while hypoxia induces HIF‐mediated SLC2A5 expression in tumor‐supportive macrophages, revealing SLC2A5‐driven fructose utilization as a shared and targetable metabolic vulnerability across malignant
Qiaoli Wu +13 more
wiley +1 more source
Inflammation and B-cell hyperactivation have been associated with non-Hodgkin lymphoma development. This prospective analysis aimed to further elucidate pre-diagnosis plasma immune marker profiles associated with non-Hodgkin lymphoma risk.
Mara M. Epstein +11 more
doaj +1 more source
A highly sensitive SERS‐based platform measures PD‐L1 expression on EpCAM+ circulating EVs from cancer patients undergoing immunotherapy. Monitoring dynamic changes after treatment reveals that reduced EpCAM+ EV PD‐L1 levels associate with improved long‐term clinical outcomes, establishing a non‐invasive approach for tracking immune checkpoint ...
Byeonggeol Mun +15 more
wiley +1 more source
T-Cell/Histiocyte Rich Large B-Cell Lymphoma –A Case Series with Review of Literature [PDF]
T-Cell/Histiocyte Rich Large B-Cell Lymphoma (THRLBCL) is a rare variant of Diffuse Large B Cell Lymphoma (DLBCL). This entity differs from the classical DLBCL in the morphology as well as immunohistochemical expression of various CD markers.
Priavadhana Rajan Prasaad +1 more
doaj +1 more source
In MYC‐enforced B‐cell lymphoma, SOX5 occupies promoter‐proximal regulatory regions and is associated with reduced chromatin accessibility at the PCNP locus. PCNP repression promotes proliferative remodeling by limiting apoptosis and cell‐cycle restraint.
Yiyou Mao +6 more
wiley +1 more source

